References
- Cousin JL, Samson M, Pilch PF, Fehlmann M (1987) Internalization of insulin receptors and HLA antigens in human hepatoma cells. Biochem J, 242, 403-10. https://doi.org/10.1042/bj2420403
- Cho N, Momose Y (2008). Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem, 8, 1483-507. https://doi.org/10.2174/156802608786413474
- Draznin B (2006). Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes, 55, 2392-7. https://doi.org/10.2337/db06-0391
- Donadon V, Balbi M, Perciaccante A, Casarin P, Zanette G (2009) Insulin resistance and hyperinsulinemia in patients with chronic liver disease and hepatocellular carcinoma. Clinical Medicine Insights: Endocrinology and Diabetes, 2, 25-33.
- Gupta SP, Mittal A, Sathian B. Jha DK (2013). Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev, 14, 7331-3. https://doi.org/10.7314/APJCP.2013.14.12.7331
- Hu, XQ, Yuan P, Luan, RS et al (2013). Calpain-10 SNP43 and SNP19 polymorphisms and colorectal cancer: a matched case-control study. Asian Pac J Cancer Prev, 14, 6673-80. https://doi.org/10.7314/APJCP.2013.14.11.6673
- Keku TO, Lund PK, Galanko J, et al (2005) Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev, 14, 2076-81. https://doi.org/10.1158/1055-9965.EPI-05-0239
- Kruk J, Czerniak U (2013). Physical activity and its relation to cancer risk: updating the evidence. Asian Pac J Cancer Prev, 14, 3993-4003. https://doi.org/10.7314/APJCP.2013.14.7.3993
- Liotta LA, Stetler-Stevenson WG (1991). Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res, 51, 5054-9.
- Ledoux S, Yang R, Friedlander G, Laouari D (2003). Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res, 63, 7284-90.
- Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A (2007). Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol, 47, 142-56. https://doi.org/10.1016/j.jhep.2007.04.002
- Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ (2007). The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin, 57, 225-41. https://doi.org/10.3322/canjclin.57.4.225
- Melin B, Cherqui G, Blivet MJ, et al (1990). Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism, 39, 1089-95. https://doi.org/10.1016/0026-0495(90)90171-8
- Macaulay SL, Polites M, Frenkel MJ, Hewish DR, Ward CW (1995). Mutagenic structure/function analysis of the cytoplasmic cysteines of the insulin receptor. Biochem J, 306, 811-20. https://doi.org/10.1042/bj3060811
- Soliman PT, Wu D, Tortolero-Luna G, et al (2006). Association between adiponectin, insulin resistance, and endometrial cancer. Cancer, 106, 2376-81. https://doi.org/10.1002/cncr.21866
- Su JL, Yang PC, Shih JY, et al (2006). The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 9, 209-23. https://doi.org/10.1016/j.ccr.2006.02.018
- Sawai H, Domae N (2011). Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. Biochem Biophys Res Commun, 411, 569-73. https://doi.org/10.1016/j.bbrc.2011.06.186
- Stockert JC, Blazquez-Castro A, Canete M, Horobin RW, Villanueva A (2012). MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta Histochem, 114, 785-96. https://doi.org/10.1016/j.acthis.2012.01.006
- Tsujimoto M, Aozasa K, Nakajima Y, Kariya M (1984). Hepatocellular carcinoma with sarcomatous proliferation showing an unusual and wide-spread metastasis. Acta Pathol Jpn, 34, 839-45.
- Turati F, Talamini R, Pelucchi C, et al (2013). Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer, 108, 222-8. https://doi.org/10.1038/bjc.2012.492
- Wilcox G (2005). Insulin and insulin resistance. Clin Biochem Rev, 26, 19-39.
- Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K (2001). Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition, 17, 590-3. https://doi.org/10.1016/S0899-9007(01)00561-5
- Yao Z, Che XC, Lu R, et al (2007). Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell. Mol Med, 13, 14-21.
Cited by
- Overcoming 5-Fu Resistance of Colon Cells through Inhibition of Glut1 by the Specific Inhibitor WZB117 vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7037
- Impact of insulin resistance on hepatocellular carcinoma vol.56, pp.4, 2015, https://doi.org/10.2957/kanzo.56.127
- 2-Deoxyglucose Reverses the Promoting Effect of Insulin on Colorectal Cancer Cells In Vitro vol.11, pp.3, 2016, https://doi.org/10.1371/journal.pone.0151115
- Insulin resistance contributes to multidrug resistance in HepG2 cells via activation of the PERK signaling pathway and upregulation of Bcl-2 and P-gp vol.35, pp.5, 2016, https://doi.org/10.3892/or.2016.4632